Skip to content
value.today

Biopharmaceutical Research Co

Formerly Biopharmaceutical Research Company, LLC

Total raised
$28 M
3 rounds on record
Latest round
$23 M
Jul 2022
First round on record
Sep 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Biopharmaceutical Research Co
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2022$23 MNo. 3$10 to $50 million

Biopharmaceutical Research Co: Raise no. 3, Jul 2022

Investors in this round

36 investors had bought by the notice of Jun 20, 2023: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Total Offering Amount includes the amount related to the conversion of notes into shares of Series A Preferred Stock. The issuance of such convertible notes was reported in September 2020 as a debt an
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,191,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • George Bennett Hodgin · Executive Officer, Director
  • Charles Bennett Schumacher · Director
  • Edward Howard Goodwin · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • North Point Mergers and Acquisitions, Inc. (CRD 133300) · San Francisco, CaliforniaSold in AZ, CA, CT, GA, KS, LA, MA, NC, NJ, NY, PA, TN, TX, WA

Signed by George Bennett Hodgin, Chief Executive Officer. Newest notice filed Jun 20, 2023 (1 amendment). Read the notice at the SEC.

equitySEC
Feb 2022$3 MNo. 2$2 to $10 million

Biopharmaceutical Research Co: Raise no. 2, Feb 2022

Investors in this round

22 investors had bought by the notice of Mar 18, 2022: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$152,130
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • George Hodgin · Executive Officer, Director
  • Charles Schumacher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • North Point Mergers and Acquisitions, Inc. (CRD 133300) · San Francisco, CaliforniaSold in CA, CT, KS, LA, MA, NC, NJ, NY, TN, TX

Remarks in the notice

  • On fees: “North Point Mergers and Acquisitions, Inc. will receive equity private placement fees corresponding to (i) a cash fee of 6% of the total investments and (ii) warrants representing 3% of the total investments.”

Signed by George Hodgin, Chief Executive Officer. Newest notice filed Mar 18, 2022 (1 amendment). Read the notice at the SEC.

equity, optionsSEC
Sep 2020$2 MNo. 1$2 to $10 million

Biopharmaceutical Research Co: Raise no. 1, Sep 2020

Investors in this round

17 investors had bought by the notice of Oct 2, 2020: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$122,700
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • George Hodgin · Executive Officer, Director
  • Charles Schumacher · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • North Point Advisors, Inc. (CRD 133300) · broker-dealer North Point Advisors, Inc. (CRD 133300) · San Francisco, CaliforniaSold in AZ, CA, CO, CT, DC, HI, IL, MA, MI, NC, NJ, NY, PA, PR, TX, UT, WA

Remarks in the notice

  • On fees: “North Point Advisors, Inc. will also receive a to be determined number of warrants to purchase shares of the issuer.”

Signed by George Hodgin, Chief Executive Officer. Newest notice filed Oct 2, 2020. Read the notice at the SEC.

debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Biopharmaceutical Research Co chose not to state its revenue in its newest notice of a funding round (Jun 2023).

    SEC Form D · Jun 2023

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Jun 2023

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Biopharmaceutical Research Co is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Biopharmaceutical Research Co
NameRoleNamed in
George Bennett HodginExecutive officerJun 2023
George HodginExecutive officerMar 2022
Charles Bennett SchumacherDirectorJun 2023
Edward Howard GoodwinDirectorJun 2023
George Bennett HodginDirectorJun 2023
Charles SchumacherDirectorMar 2022
George HodginDirectorMar 2022